The new patent extends intellectual property protection for the company’s noninvasive lung cancer detection technology in Asia, complementing its existing Chinese patent.
Key Investor Takeaways
- bioAffinity Technologies (NASDAQ:BIAF) has received a Hong Kong patent covering core technology used in its CyPath Lung diagnostic test.
- The patent complements protection granted in China in 2025, expanding the company’s intellectual property position in Asia.
- CyPath Lung uses flow cytometry and fluorescent markers to assess the likelihood of lung cancer in patients with suspicious lung nodules.
- The company identifies Asia as a potential expansion market, citing approximately 1.6 million new lung cancer cases annually across the region.
- The announcement does not include regulatory approvals, commercial agreements or revenue projections for Hong Kong or China.
Why BIAF Stock Is in Focus
bioAffinity Technologies announced that the Hong Kong Intellectual Property Department has granted a patent covering technology underlying its CyPath Lung noninvasive cancer diagnostic.
Hong Kong Patent No. HK40048460, titled “System and Method for Determining Lung Health,” protects specified methods involving antibodies, the fluorescent porphyrin TCPP and flow cytometry to identify lung cancer cells in sputum samples.
The technology forms the scientific foundation of CyPath Lung, a test designed to help physicians evaluate the likelihood of malignancy in lung nodules identified through low-dose CT scans or incidental imaging.
The Hong Kong patent adds to the company’s international intellectual property portfolio, which includes patents and pending applications in the United States, Australia, Canada, China, the European Union, Japan, Mexico and Singapore.
bioAffinity is seeking to protect its diagnostic technology across multiple markets as it develops its commercial activities.
Why This Matters for Investors
The patent strengthens bioAffinity’s intellectual property position in a region the company identifies as a potential market for lung cancer diagnostics.
With patent protection now established in both Hong Kong and China, bioAffinity has additional legal protection for specified aspects of its technology as it considers opportunities in Asia.
However, patent protection does not itself establish a commercial presence or authorize a diagnostic product for sale.
The announcement does not disclose a market-entry timetable, regulatory pathway, distribution partnership or expected financial contribution from the region.
CyPath Lung’s existing clinical data provide context for the technology being protected.
In a published clinical trial involving high-risk patients with indeterminate lung nodules smaller than 20 millimeters, the test demonstrated:
- Sensitivity of 92%.
- Specificity of 87%.
- Overall accuracy of 88%.
- Negative predictive value of 99%.
These results relate to the test’s use in lung cancer detection and have not been separately validated for post-treatment surveillance.
CyPath Lung is currently marketed as a Laboratory Developed Test by bioAffinity subsidiary Precision Pathology Laboratory Services. It is intended to support clinical decision-making rather than serve as a standalone diagnostic.
For investors, the patent grant represents an intellectual property development rather than an immediate change in the company’s reported commercial performance.
Its longer-term significance could depend on whether bioAffinity converts its expanded patent portfolio into regulatory progress, partnerships and commercial activity in additional markets.
What to Watch Next
The next developments will involve any announced plans to commercialize CyPath Lung in Hong Kong, China or other Asian markets.
Investors can monitor potential regulatory submissions, distribution arrangements and commercial partnerships that could establish a pathway into the region.
Additional patent grants and updates on the company’s broader diagnostic pipeline may also provide insight into how bioAffinity intends to use its intellectual property portfolio.
The company has not announced a timetable for Asian market entry or quantified the potential revenue associated with the newly granted patent.